Fralex Therapeutics files for proposed initial public offering

By Jennifer Chiou

New York, Oct. 26 - Fralex Therapeutics Inc. announced it filed a preliminary prospectus with the securities regulatory authorities in each of the provinces of Canada for a proposed initial public offering.

Westwind Partners Inc. and Desjardins Securities Inc. are leading the syndicate of underwriters, which includes Canaccord Capital Corp., Dundee Securities Corp. and Jennings Capital Inc.

The Toronto-based medical device company is focused on neuromodulation therapy for chronic pain known as Complex Neural Pulse.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.